Cargando…

High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV

PURPOSE: Casirivimab/imdevimab (REGN-COV), a cocktail of neutralizing antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, was shown to be an effective treatment and post-exposure prophylaxis measure for coronavirus disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Hiroaki, Miyata, Nobuyuki, Yoshimura, Yukihiro, Tachikawa, Natsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856927/ https://www.ncbi.nlm.nih.gov/pubmed/35181864 http://dx.doi.org/10.1007/s15010-022-01779-x

Ejemplares similares

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
por: Weinreich, David M., et al.
Publicado: (2020)

Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab
por: Horiuchi, Hiroshi, et al.
Publicado: (2022)

Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan
por: Yoshimura, Yukihiro, et al.
Publicado: (2021)

Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2
por: Arikawa, Shigehisa, et al.
Publicado: (2022)

REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan
por: Sakurai, Ayana, et al.
Publicado: (2022)

Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability
por: Nguyen, Hung, et al.
Publicado: (2022)

Clinical characteristics of the coronavirus disease 2019 (COVID-19) outbreak on a cruise ship
por: Yoshimura, Yukihiro, et al.
Publicado: (2020)

Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
por: Furukawa, Hiroshi, et al.
Publicado: (2022)

On-admission SARS-CoV-2 RNAemia as a single potent predictive marker of critical condition development and mortality in COVID-19
por: Miki, Shoji, et al.
Publicado: (2021)

Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
por: Kurshan, Ashwini, et al.
Publicado: (2023)

Comparison of the levels of neopterin, CRP, and IL-6 in patients infected with and without SARS-CoV-2
por: Hara, Satoshi, et al.
Publicado: (2022)

Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults
por: Jonsdottir, Hulda R., et al.
Publicado: (2021)

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
por: Baum, Alina, et al.
Publicado: (2020)

Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals
por: Grunau, Brian, et al.
Publicado: (2022)

An autopsy case of COVID-19-like acute respiratory distress syndrome after mRNA-1273 SARS-CoV-2 vaccination.
por: Yoshimura, Yukihiro, et al.
Publicado: (2022)

Human antibodies can neutralize SARS-CoV-2
por: Catalan-Dibene, Jovani
Publicado: (2020)

A cocktail of antibodies for COVID-19 therapy
por: Matthews, Dean B.
Publicado: (2020)

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma
por: Salazar, Eric, et al.
Publicado: (2020)

The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
por: Nurmi, Visa, et al.
Publicado: (2023)

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
por: Baum, Alina, et al.
Publicado: (2020)

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2022)

Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents
por: Dyer, Adam H., et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Diseases affecting patients returning from abroad: Experience of a travel clinic in Japan from 2004 to 2014
por: Yoshimura, Yukihiro, et al.
Publicado: (2017)

Quantity of Vaccine Poliovirus Shed Determines the Titer of the Serum Neutralizing Antibody Response in Indian Children Who Received Oral Vaccine
por: Giri, Sidhartha, et al.
Publicado: (2018)

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
por: Zhang, Haiying, et al.
Publicado: (2022)

Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection
por: Monroe, Jonathon M., et al.
Publicado: (2022)

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
por: Counoupas, Claudio, et al.
Publicado: (2022)

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
por: Tada, Takuya, et al.
Publicado: (2021)

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants
por: Liu, Junli, et al.
Publicado: (2021)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
por: Dong, Jinhui, et al.
Publicado: (2021)

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
por: Kobashi, Yurie, et al.
Publicado: (2022)

Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron
por: Adachi, Eisuke, et al.
Publicado: (2022)

Neutralizing antibodies targeting SARS-CoV-2 spike protein
por: Xiaojie, Shi, et al.
Publicado: (2021)

SARS-CoV-2 spike S2-specific neutralizing antibodies
por: Li, Chia-Jung, et al.
Publicado: (2023)

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants
por: Qu, Yuanyuan, et al.
Publicado: (2021)

Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy
por: Taha, Yusri, et al.
Publicado: (2021)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
por: Anichini, Gabriele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pj5mm0t8lt4o5253002n0aigkq